Bio-Rad Third-Quarter 2026 Earnings Results Conference Call and Webcast - BIO-RAD LABORATORIES INC

Financial Performance:

• Third quarter 2026 total revenue was $656 million, representing a 0.5% increase on a reported basis and 0.7% on a currency-neutral basis, marking the first currency-neutral growth quarter of the year.
• Life Science revenue was $255 million (down 2.8% reported), while Clinical Diagnostics revenue was $402 million (up 2.7% reported), driven by Quality Systems and Diabetes products.
• Non-GAAP gross margin expanded to 54.5% from 53.5% year-over-year, despite a GAAP margin decline to 50.1% due to restructuring charges.
• Non-GAAP operating margin improved to 12.8% from 11.8% year-over-year, with sequential improvement from Q2's 12.5%.
• Non-GAAP net income reached $72 million ($2.65 diluted EPS), up from $61 million ($2.26 diluted EPS) in the prior year; GAAP operating loss was $15 million due to a $50 million non-cash impairment of intangible assets.
• SG&A was $257 million (39.2% of sales) on a GAAP basis, with non-GAAP SG&A at $214 million (32.6% of sales); R&D was $71 million (10.9% of sales), with non-GAAP R&D at $60 million.
• Full-year free cash flow is guided for $290–$340 million; $210 million generated through the first nine months.

Guidance and Future Outlook:

• Full-year 2026 currency-neutral revenue growth is reaffirmed between -3% and +0.5%, expected to close near the midpoint.
• Life Science segment currency-neutral growth is guided between -3% and -1%; Clinical Diagnostics between -3% and +1%.
• Q4 2026 revenue is expected to grow 5–6% sequentially on a reported basis, despite a sequential decline in process chromatography.
• Full-year non-GAAP gross margin is guided for the upper half of 53–54%; Q4 non-GAAP margin is expected to decline sequentially due to product mix shift toward instruments and higher fuel prices.
• Full-year non-GAAP operating margin is guided for the upper half of 10–12%; Q4 SG&A expected flat vs. Q3, with a $3 million sequential increase in R&D.
• Management targets positive organic growth in 2027 and operating margins above 20% long-term; full 2027 guidance to be provided at year-end.
• Tariff refunds are expected to be recognized in GAAP results at year-end only, with no pass-through to customers.

Business Segments and Product Lines:

• Droplet Digital PCR (ddPCR) instrument revenue grew >20% for the third consecutive quarter, driven by conversions from qPCR and competitive wins; the portfolio is up 7% on a currency-neutral basis.
• Life Science performance excluding process chromatography grew 2.5% currency-neutral, driven by the genomics portfolio; DDPCR is viewed as a durable long-term growth driver.
• Launched ChemiDot Pro, a flagship Western blot imaging system utilizing AI-trained algorithms to improve consistency, accelerated by two quarters over original timelines.
• Expanded the Foresight Pro pre-packed chromatography portfolio to include Renuvia resins, broadening formats available to customers.
• Clinical Diagnostics growth was supported by Quality Systems and Diabetes products; Quality Controls remains a market leader globally.
• Process chromatography revenue improved sequentially throughout 2026, though a Q4 sequential decline is expected; full-year revenue should improve year-over-year.
• Recorded a $50 million non-cash impairment on intangible assets in Life Science as part of a disciplined portfolio prioritization strategy.

Market and Competitive Landscape:

• End markets remain mixed: Biopharma shows signs of gradual recovery with improving customer activity; Academic/Government funding in the U.S. remains challenging with NIH outlays down ~15%.
• China market returned to growth in Q3 driven by order timing and favorable comparisons, though pricing pressure from NISA guidelines creates a "middle single-digit millions" revenue impact risk for 2027.
• EMEA Middle East faces elevated logistics costs and supply chain disruptions expected to continue into 2027.
• U.S. academic and government markets face continued funding constraints; final Medicare reimbursement rates (PAMA) expected November, with limited anticipated indirect impact in 2027.
• AI adoption by customers is viewed as a demand driver, specifically in the transition from in silico modeling to wet lab validation.

Risks and Challenges:

• Academic and government end markets are expected to remain soft in 2026 and beyond, with no recovery assumed in Q4.
• China regulatory pricing pressure and a preference for domestic suppliers continue to create a challenging operating environment.
• Supply chain disruptions and elevated logistics costs in the Middle East are expected to persist into 2027.
• Pull-through of consumables has not yet normalized; management expects normalization in 2027 as instrument installations ramp.
• A sequential decline in gross margin is projected for Q4 due to product mix shifts and higher fuel costs.
• The company is not updating forward-looking statements; actual results may differ materially due to risks and uncertainties.

Management Commentary and Tone:

• Tone is cautiously optimistic, acknowledging modest revenue growth while emphasizing strong progress in operational metrics and specific product lines.
• Management expressed confidence in the durability of the ddPCR growth driver and the long-term opportunity in clinical and applied testing.
• Emphasized three operational priorities: strengthening execution, improving cost structure, and increasing enterprise productivity via AI.
• CEO Norman Schwartz noted progress in innovation pipeline acceleration and board evaluation for additional experience in life science and diagnostics.
• Management confirmed active and productive dialogue with Elliott Management, stating broad alignment on objectives.
• Executives reiterated commitment to returning to 20%+ operating margins while continuing to invest in innovation and sustainable growth.

Analyst Questions and Answers:

• 2027 Revenue Outlook: Management clarified that while specific 2027 guidance is withheld until year-end, the strategic focus is driving towards positive growth rates and margin expansion.
• ddPCR Sustainability: Executives expressed strong conviction in continued instrument growth despite challenging comps, citing expanding customer base and incomplete platform utilization as key drivers.
• China & PAMA Impact: Q3 growth in China was driven by timing; China pricing guidelines expected to impact revenue by mid-single-digit millions in 2027. U.S. PAMA rates not yet impacting purchasing behavior.
• Capital Allocation: Share repurchases will be opportunistic rather than systematic; M&A strategy targets $100–$500 million revenue deals that offer differentiation and margin expansion.
• Sartorius Stake: Management maintains the view that the stake is a monetizable asset and would monetize if a scenario presents value creation.
• Restructuring: The $30–$35 million net reliance savings target remains intact, with full realization expected starting in 2028.

Other Key Points:

• Non-GAAP financial measures exclude changes in the equity value of the Sartorius AG stake.
• A supplemental earnings presentation is available on the company's investor relations website.
• The company will attend the UBS Global Healthcare Conference in the following week.
• The board is actively evaluating candidates to expand its composition with broader operational experience in life sciences and diagnostics.